৳ ০.০০
আপনার সব স্বাস্থ্যসেবার সমাধান — এখন এক জায়গাতেই
১০৬৫৭
info@shukhee.com
টেলিকম ভবন, ৫৩/১, বক্স নগর, ঢাকা-১২১৬
৳ ০.০০
১০৬৫৭
info@shukhee.com
টেলিকম ভবন, ৫৩/১, বক্স নগর, ঢাকা-১২১৬



Quantity:
Products
Payment
Delivery
Indications
As an adjunct to diet in adults with primary non‑familial hyperlipidemia to reduce LDL‑C.
Alone or with other LDL‑C lowering therapies in patients with homozygous familial hypercholesterolemia (HoFH) to reduce LDL‑C.
Pharmacology Rosuvastatin lowers plasma cholesterol and lipoprotein levels by inhibiting HMG‑CoA reductase and cholesterol synthesis in the liver, while increasing hepatic LDL receptors to enhance LDL uptake and catabolism. Ezetimibe reduces blood cholesterol by inhibiting intestinal absorption of cholesterol via the sterol transporter.
Dosage & Administration
Range: 5/10 mg to 40/10 mg orally once daily.
Severe renal impairment (not on dialysis): Start at 5/10 mg daily; maximum 10/10 mg daily.
Tablets must be swallowed whole.
Administer at least 2 hours before or 4 hours after bile acid sequestrants.
Pediatric use: Not established.
Geriatric use: No dosage adjustment required.
Interactions
Avoid with cyclosporine or gemfibrozil.
Dosage modifications required with certain antivirals, darolutamide, regorafenib.
Niacin, fibrates, colchicine increase risk of myopathy and rhabdomyolysis.
Contraindications
Active liver disease or decompensated cirrhosis.
Hypersensitivity to any component.
Side Effects Common: Headache, nausea, myalgia, arthralgia, dizziness, constipation, abdominal pain, diarrhea, sinusitis, fatigue, influenza, back pain.
Pregnancy & Lactation Contraindicated in pregnancy. Not recommended during breastfeeding.
Precautions & Warnings Risk of myopathy and rhabdomyolysis increases with age ≥65, hypothyroidism, renal impairment, drug interactions, and high dosage. Monitor CK levels. Hepatic dysfunction may occur; monitor liver enzymes.
Use in Special Populations
Hepatic impairment: Contraindicated in acute liver failure or decompensated cirrhosis.
Renal impairment: Severe impairment (CrCl <30 mL/min/1.73 m², not on dialysis): Start at 5/10 mg daily; max 10/10 mg daily. No adjustment for mild/moderate impairment.
Drug Class
Combination of a statin (Rosuvastatin) and a cholesterol absorption inhibitor (Ezetimibe).
Belongs to the class of lipid-lowering agents.
Purpose
Used to treat hyperlipidemia (high cholesterol).
Helps reduce LDL cholesterol (“bad cholesterol”) more effectively than either drug alone.
Prescribed to lower the risk of heart attack, stroke, and other cardiovascular diseases.
Mechanism
Rosuvastatin: Blocks HMG-CoA reductase in the liver, reducing cholesterol production.
Ezetimibe: Prevents absorption of cholesterol from the intestine.
Together, they provide dual action—less cholesterol made in the liver and less absorbed from food.
Advantages
Stronger LDL reduction: More effective than statin alone.
Convenient combination: Two medicines in one tablet reduce pill burden.
Cardiovascular protection: Helps prevent complications in patients with high cholesterol or existing heart disease.
Well tolerated: Generally safe with proper monitoring.
Dose:
Commonly available as Rosuvastatin (5–20 mg) + Ezetimibe (10 mg) tablets.
Usual dose: Once daily, taken with or without food.
Exact dosage must be prescribed by a doctor depending on cholesterol levels and patient condition.




Stronger LDL reduction: Lowers “bad cholesterol” (LDL) more effectively than statin alone.
Dual mechanism: Rosuvastatin reduces cholesterol production in the liver, while Ezetimibe blocks absorption from food.
Cardiovascular protection: Helps reduce risk of heart attack, stroke, and other complications.
Convenient combination: Two medicines in one tablet, reducing pill burden.
Improves treatment response: Useful for patients who do not reach target cholesterol levels with statin alone.
Well tolerated: Generally safe with proper monitoring of liver function and muscle health.





